WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC
Status:
Recruiting
Trial end date:
2026-05-30
Target enrollment:
Participant gender:
Summary
The aim of this trial is to evaluate the safety of WX-0593 combined with concurrent
chemoradiotherapy in unresectable, locally advanced non-small cell lung cancer (NSCLC) with
activating mutation of ALK or ROS1. This trial consists of two parts. In Part 1,
approximately 8 patients will be included and receive WX-0593 maintenance until disease
progression or unacceptable toxicity. In Part 2, approximately 32 patients will be included
and receive WX-0593 monotherapy for 1-2 cycles and subsequently with concurrent
chemoradiation, followed by WX-0593 maintenance until disease progression or unacceptable
toxicity.